Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-27T05:35:41.412Z Has data issue: false hasContentIssue false
  • English
  • Français

Association of Psilocybin Use in Adolescents with Major Depressive Episode

Published online by Cambridge University Press:  01 September 2022

K. Shah ,
C. Trivedi ,
D. Kamrai ,
M. Akbar  and
W. Tankersley
K. Shah*
Affiliation:
Griffin Memorial Hospital, Psychiatry, Norman, United States of America
C. Trivedi
Affiliation:
Texas Tech University Health Science Center at Permian Basin, Psychiatry, Midland, United States of America
D. Kamrai
Affiliation:
Griffin Memorial Hospital, Psychiatry, Norman, United States of America
M. Akbar
Affiliation:
Griffin Memorial Hospital, Psychiatry, Norman, United States of America
W. Tankersley
Affiliation:
Griffin Memorial Hospital, Psychiatry, Norman, United States of America
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Psilocybin is a psychedelic drug found in mushrooms, often referred to as magic mushrooms due to its visual and auditory hallucinations effects upon ingestion. It is a Schedule I drug per DEA, and the FDA has not approved psilocybin for medicinal purposes. However, recent studies have shown promising therapeutic use to treat depression.

Objectives

To identify current use, prevalence, and its association with depression in adolescents.

Methods

The National Survey on Drug Use and Health survey data from 2008-18 studied adolescent data (12-17 years), who responded, “ever used psilocybin (mushrooms)” and “lifetime major depressive episode (MDE).” The association between the psilocybin use and MDE status was analyzed in SAS 9.4 through multivariate logistic regression for odds ratio (OR) and 95% confidence interval (CI).

Results

A total of 172745 adolescents were included in this study, of which 2469 ever used psilocybin in their lifetime, and 170276 responded no lifetime use. The psilocybin ever lifetime users were 17 years old (42%vs.17%,p<0.001), male (60%vs.51%,p<0.001), and non-Hispanic White (71%vs.55%,p<0.001) in comparison to non-users. Among psilocybin user group, 31% of respondents had lifetime MDE, compared to 16% of the lifetime psilocybin non-user group participants (p<0.001). The odds of association of psilocybin use among participants with MDE were 2.17 times compared to those without MDE (CI: 1.93-2.44,p<0.001).

Conclusions

We identified a significant association between psilocybin use and MDE among adolescents, which raises public health concerns about its illegal use, abuse, and toxicity potential. Future clinical studies should assess its clinical safety, efficacy, and addictive properties.

Disclosure

No significant relationships.

Keywords

MDDPsilocybinDepressionAdolescents
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S329
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.